Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab plus Gebasaxturev and Pembrolizumab Monotherapy in Stage IIIB–D Melanoma By Ogkologos - January 21, 2025 796 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a substudy 02C of the KEYMAKER-U02 trial Source RELATED ARTICLESMORE FROM AUTHOR Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer MOST POPULAR Most Cases of Venous Thromboembolic Events, Elevated Aminotransferases, and Interstitial Lung... May 8, 2021 Sentinel Lymph Node Biopsy Navigated Neck Dissection Is Not Inferior to... April 22, 2021 How Running and Training for a Marathon Helped Me Cope After... August 22, 2023 Cancer Patient Dresses Up To Cheer Others In Chemo & The... March 18, 2019 Load more HOT NEWS Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with... EMA Recommends Extension of Indications for Pembrolizumab England moves to a single-dose HPV vaccine Using Technology to Find Cancers Early and Exercise Improves Sexual Health...
